Obeticholic Acid 5 mg for PBC: Dosage, Risks, and Current Status

　　Obeticholic acid 5 mg was once one of the starting doses for primary biliary cholangitis(PBC),but whether it can be taken long term cannot be decided from the tablet strength alone.The drug carries a risk of serious liver injury,and its marketing approval was withdrawn in the United States in 2025,so long-term use calls for particular caution.

　　1.What the 5 mg dose was used for

　　Obeticholic acid was previously used to treat some adults with PBC.In the former labeling,5 mg once daily was the starting amount for certain patients,with later adjustments guided by treatment response,tolerability,and liver function.These dose details reflect a past treatment approach and are not a basis for self-medication today.

　　2.A lower dose is not the same as a safer one

　　A lower dose does not rule out the risk of serious liver injury.The FDA reported severe events during obeticholic acid therapy,including hepatic decompensation,liver failure,and liver transplantation,and stressed the need for close liver function monitoring.The 5 mg dose therefore cannot be assumed suitable for long-term use in every patient.

　　3.What to monitor during long-term use

　　Previous management focused on alkaline phosphatase,bilirubin,and other liver function measures,together with symptoms such as jaundice,dark urine,persistent nausea,and vomiting.Any sign suggesting liver injury or disease progression warrants prompt medical evaluation.

　　4.Can it still be taken?

　　Approval was withdrawn in the United States in 2025,and regulatory status elsewhere should be verified separately.Patients currently taking the drug should not increase the dose on their own or continue long-term use based solely on an old prescription.They should confirm the current status of the medicine and discuss alternative treatment options with their care team.